Lexicon Pharmaceuticals, Inc. LXRX
Set alert
As of Nov 3, 12:34 PM ET
- YTD
- +27.53%
- 1 year
- +7.84%
- Open
- 1.45
- Prev close
- 1.44
- Mkt cap
- 652.57M
- Vol
- 336.12K
- Avg vol
- 2.71M
- EPS
- -0.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.45
- High
- 1.52
- Forward P/E
- -11.86
- Beta
- 1.03
- Short ratio
- 11.53
- Inst. own
- 83.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 2.33
- 200-d avg
- 1.78
- 1y target
- 3.86
5D chart
Signals (52)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 9:35 AM | 1 day ago |
| RSI: Overbought | Oct 30, 3:50 PM | 3 days ago |
| RSI: Overbought | Oct 30, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 4 days ago |
| RSI: Oversold | Oct 30, 1:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 30, 12:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 4 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 4 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 4 days ago |
| RSI: Overbought | Oct 29, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:20 PM | 4 days ago |
Newest 20 of 52.
News
5 days ago globenewswire.com
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its…
-
1 week ago benzinga.com
Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing…
1 week ago globenewswire.com
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study…
-
1 week ago benzinga.com
Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second preclinical study shows inhibitory effects of…
1 week ago globenewswire.com
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of…
3 weeks ago defenseworld.net
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% – Here’s What Happened
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report)'s share price fell 5.2% during trading on Monday. The company traded as low as $1.72 and last traded at $1.7250. Approximately 1,402,888…
4 weeks ago benzinga.com
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript
Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.…
1 month ago seekingalpha.com
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. LXRX anticipates NDA resubmission for ZYNQUISTA in T1D by Q4 2026, contingent on STENO1…
1 month ago fool.com
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
He feels it's a clear buy at the current price. In his view, sotagliflozin has excellent potential to win FDA approval for a new indication.
1 month ago defenseworld.net
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of “Hold” from Brokerages
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the company, MarketBeat Ratings…
1 month ago benzinga.com
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
1 month ago benzinga.com
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).
-
1 month ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Overweight rating and announces Price Target of $8.
1 month ago defenseworld.net
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Pharmaceuticals (NASDAQ: LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first…
1 month ago marketbeat.com
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first…
1 month ago benzinga.com
Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures rose, but Beta Bionics fell 7.1% after pricing a stock offering; several other stocks also declined in premarket trading.
-
1 month ago benzinga.com
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
1 month ago seekingalpha.com
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
2 months ago globenewswire.com
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences…
2 months ago globenewswire.com
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure
2 months ago globenewswire.com
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
2 months ago seekingalpha.com
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets
Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D,…
2 months ago marketbeat.com
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III…
2 months ago seekingalpha.com
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.01 per share a year ago.
-
2 months ago benzinga.com
Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over earnings…
2 months ago globenewswire.com
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA ® in type 1 diabetes nearing completion Phase 1 clinical development of…
3 months ago globenewswire.com
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday,…
-
3 months ago benzinga.com
Lexicon Pharmaceuticals Completes Randomization Of Patients In Its Pivotal Phase 3 'Sotagliflozin In Patients With Symptomatic Obstructive And Non-Obstructive Hypertrophic Cardiomyopathy' Clinical Trial
The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries. The primary efficacy endpoint will assess improvement in symptoms for the entire…
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
5 months ago benzinga.com
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $2.3 to $3.1.
-
6 months ago benzinga.com
Lexicon Pharmaceuticals Q1 Sales $1.090M Miss $9.380M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly sales of $1.090 million which missed the analyst consensus estimate of $9.380 million by 88.38 percent. This is a 13.63 percent decrease over…
-
6 months ago benzinga.com
Lexicon Pharmaceuticals To Present Data From Its PROGRESS Phase 2b Trial Of Pilavapadin In Diabetic Peripheral Neuropathic Pain To Support Selection Of Pilavapadin 10 Mg As Optimal Dose For Phase 3 Development
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) supporting the selection of…
7 months ago benzinga.com
Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
9 months ago benzinga.com
Gold Tumbles Over 6%; Apple Posts Upbeat Earnings
Gold Tumbles Over 6%; Apple Posts Upbeat Earnings
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
9 months ago benzinga.com
Progress Software Posts Upbeat Q4 Earnings, Joins ServisFirst Bancshares, Zura Bio And Other Big Stocks Moving Higher On Wednesday
Progress Software Posts Upbeat Q4 Earnings, Joins ServisFirst Bancshares, Zura Bio And Other Big Stocks Moving Higher On Wednesday
11 months ago benzinga.com
Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
11 months ago benzinga.com
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session
12 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
1 year ago benzinga.com
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1…
1 year ago benzinga.com
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst
U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
Earnings Scheduled For November 12, 2024
Earnings Scheduled For November 12, 2024